Table 1.
Baseline demographic and clinical characteristics of patients with and without conversion from anti-HBc- to anti-HBc+
| Characteristic | Conversion (n = 29) |
No Conversion (n = 170) |
Total (n = 199) |
p |
|||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | ||
| Age at baseline anti-HBc test, median (range) | 52 (20–73) | 51 (20–79) | 51 (20–79) | 0.99* | |||
| Race/ethnicity, n (%) | |||||||
| White | 19 | (66) | 111 | (65) | 130 | (65) | 0.90 |
| Hispanic | 6 | (21) | 32 | (19) | 38 | (19) | |
| Black | 4 | (13) | 18 | (11) | 22 | (11) | |
| Asian | 0 | (0) | 3 | (2) | 3 | (2) | |
| Other | 0 | (0) | 6 | (4) | 6 | (3) | |
| Sex, n (%) | |||||||
| Female | 9 | (31) | 65 | (38) | 74 | (37) | 0.54 |
| Male | 20 | (69) | 105 | (62) | 125 | (63) | |
| Cancer type, n (%) | |||||||
| Solid tumor (not HCC) | 1 | (3) | 10 | (6) | 11 | (6) | 1.00 |
| Hematologic malignancy | 28 | (97) | 160 | (94) | 188 | (94) | |
| Rituximab, n (%) | |||||||
| No | 15 | (52) | 101 | (59) | 116 | (58) | 0.54 |
| Yes | 14 | (48) | 69 | (41) | 83 | (42) | |
| SCT, n (%) | |||||||
| Allogeneic | 16 | (55) | 95 | (56) | 111 | (56) | 0.77 |
| Autologous | 5 | (17) | 37 | (22) | 42 | (21) | |
| No SCT | 8 | (28) | 38 | (22) | 46 | (23) | |
NOTE: HBV: hepatitis B virus. SCT: stem cell transplant. IVIG: intravenous immunoglobulin. HCC: hepatocellular cancer. anti-HBc: hepatitis B core antibody.
*
P-values are from Fisher’s exact test, with the exception of the test for the association between anti-HBc status and age, which was from a Wilcoxon rank sum test.